Literature DB >> 10460927

Antimicrobial resistance among community-acquired pneumonia isolates in Europe: first results from the SENTRY antimicrobial surveillance program 1997. SENTRY Participants Group.

A C Fluit1, F J Schmitz, M E Jones, J Acar, R Gupta, J Verhoef.   

Abstract

OBJECTIVE: The SENTRY antimicrobial surveillance program was established to monitor the occurrence and antimicrobial susceptibility of bacterial pathogens via an international network of sentinel hospitals.
MATERIAL AND METHODS: Microorganisms were forwarded to the reference laboratory for testing against various antimicrobial agents using broth microdilution. Twenty European hospitals referred 286 Streptococcus pneumoniae, 309 Haemophilus influenzae, and 167 Moraxella catarrhalis isolates during the first 10 months of the study, starting in April 1997.
RESULTS: Seven percent of the S. pneumoniae isolates were highly resistant to penicillin, and 21% showed intermediate resistance. The highly resistant pneumococcal isolates came from Coimbra, Barcelona, Athens, and London, whereas the intermediate penicillin-resistant isolates were received from all participating countries. The incidence of intermediate penicillin-resistant pneumococci was lowest in Lausanne, Freiburg and Duesseldorf, London, and Utrecht and highest in southern European countries. Fifty-five percent of the penicillin-resistant S. pneumoniae were also resistant to erythromycin, and 35% to clindamycin. Sparfloxacin, trovafloxacin, levofloxacin, and vancomycin were fully active against pneumococcal isolates. Haemophilus influenzae isolates were generally highly susceptible to most of the antibiotics tested, and 92% of the M. catarrhalis isolates were resistant to penicillin. Susceptibility to cephalosporins, ciprofloxacin, levofloxacin, and rifampicin was 100%.
CONCLUSION: Penicillin may no longer be the first-choice drug for empirical treatment of pneumococcal infections. The newer fluoroquinolones may play a role in the empirical treatment of community-acquired pneumonia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10460927     DOI: 10.1016/s1201-9712(99)90037-1

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  7 in total

Review 1.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.

Authors:  M E Jones; A M Staples; I Critchley; C Thornsberry; P Heinze; H D Engler; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Two-center collaborative evaluation of the performance of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of Enterococcus spp. and Staphylococcus spp.

Authors:  Anne-Marie Fahr; Ulrich Eigner; Martina Armbrust; Alexandra Caganic; Giuseppe Dettori; Carlo Chezzi; Luca Bertoncini; Magda Benecchi; Maria Grazia Menozzi
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

4.  Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Ian A Critchley; James A Karlowsky; Deborah C Draghi; Mark E Jones; Clyde Thornsberry; Kate Murfitt; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 5.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Methodology and Early Results of the First Surveillance Program on Prevention and Control of Antimicrobial Resistance in Isfahan, Iran: The IAS-I Study.

Authors:  Sayed Nasser Mostafavi; Soodabeh Rostami; Behrooz Ataei; Sina Mobasherizadeh; Azam Cheraghi; Somayeh Haghighipour; Samereh Nouri; Arezoo Pourdad; Parisa Ataabadi; Naser Almasi; Leila Heidary; Kourosh Naderi; Setareh Korangbeheshti; Shiva Navabi; Laleh Masssah; Zohreh Norouzi; Mehrnoush Bakhtiyaritabar; Saeed Moayednia; Dariush Shokri; Mahin Mikhak; Majid Rahmani; Mohammad Hashemi; Reza Etminani; Nasrin Ahmadi; Mahboubeh Akhlaghi; Roya Kelishadi
Journal:  Int J Prev Med       Date:  2020-09-03

Review 7.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.